Biotech Investment Specialist 02-about
founded 2010

Bringing Dramatic Advances
in the Biotechnology Sector

Dramatic advances in the biotechnology sector are creating an unprecedented opportunity to translate scientific breakthroughs into transformative medicines.

Aquilo Capital invests in drug development companies that harness the power of cutting-edge science to address urgent medical needs. We employ deep sector expertise and a disciplined, value-oriented process to identify extraordinary biotech companies with the potential to alter the practice of medicine in profound ways. In our view, these investment opportunities offer both substantial risk-adjusted returns as well as paradigm-changing therapeutics for patients and for society.

Biotech Investment Fund opportunities
EU Opportunities

Expanding European Opportunity

The unique evolution of research in the European landscape has created a scaffold for quality innovation, resilience, and the resources to deliver results efficiently


Competitive Research Landscape

750,000 research publications in Europe, more than 2 times the number in the US

Global Innovation Capture

25% of biotech patents granted between 2012 and 2021 were in Europe

Execution Growth

8.2% yearly growth in IND submissions since 2014

Focus on Novelty

20–25% annual growth in new modalities in early clinical pipeline over the past 5 years

Talent Capture

43 of the top 100 life-science universities are in Europe (compared to 34 in the US)

We Translate Opportunities Into Scientific Breakthroughs